Pharvaris N.V. (PHVS) Presents at 2026 Global Angioedema Leadership Conference - Slideshow

Pharvaris N.V. presented at the 2026 Global Angioedema Leadership Conference, sharing a slide deck outlining its latest developments in hereditary angioedema (HAE) treatments. The presentation focused on the company’s clinical pipeline, including updates on its lead drug candidate, PHA121, a subcutaneous bradykinin B2 receptor antagonist for HAE attack prevention. Key data highlighted Phase 3 trial results, demonstrating PHA121’s efficacy in reducing attack frequency, with a safety profile supporting long-term use. Pharvaris emphasized its global regulatory strategy, targeting FDA and EMA submissions in 2026, aiming for accelerated approval pathways. The slides also underscored patient-centric innovations, such as at-home administration and digital health tools to improve adherence and monitoring.